SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
NewTimeSpace: SSY Group Limited (02005.HK) announced a voluntary announcement that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the National Medical Products Administration (NMPA) of China.The product is classified as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first approval among domestic enterprises, mainly indicated for the treatment of respiratory failure.
NewTimeSpace : SSY Group Limited (02005.HK) issued a voluntary announcement on March 3, 2026, stating that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the NMPA.
The product is a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first product of its kind approved by a domestic enterprise, and is mainly used for the treatment of respiratory failure.
Tags：
- SSY Group Signs Letter of Intent with Longhai Pharma for Four Biosimilars Including Ustekinumab and Dupilumab
- SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops
- SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise
- SSY Group (02005.HK): Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection Obtain Drug Production Registration Approvals
- SSY GROUP (02005.HK): Calcium Chloride API Approved for Registration by NMPA
